PML/RARA oxidation and arsenic binding initiate the antileukemia response of As2O3.
about
Arsenic-induced SUMO-dependent recruitment of RNF4 into PML nuclear bodiesThe SUMO E3-ligase PIAS1 regulates the tumor suppressor PML and its oncogenic counterpart PML-RARANovel human BTB/POZ domain-containing zinc finger protein ZBTB1 inhibits transcriptional activities of CREJTV1 co-activates FBP to induce USP29 transcription and stabilize p53 in response to oxidative stressFrom an old remedy to a magic bullet: molecular mechanisms underlying the therapeutic effects of arsenic in fighting leukemiaTo breathe or not to breathe: the haematopoietic stem/progenitor cells dilemmaThe cell biology of disease: Acute promyelocytic leukemia, arsenic, and PML bodiesDual effect of oxidative stress on leukemia cancer induction and treatmentPerspectives of differentiation therapies of acute myeloid leukemia: the search for the molecular basis of patients' variable responses to 1,25-dihydroxyvitamin d and vitamin d analogsProtein quality control in the nucleusMechanisms of action and resistance to all-trans retinoic acid (ATRA) and arsenic trioxide (As2O 3) in acute promyelocytic leukemia.Targeting of leukemia-initiating cells in acute promyelocytic leukemiaSecondary mutations as mediators of resistance to targeted therapy in leukemiaArsenic binding to proteinsArsenic trioxide and resveratrol show synergistic anti-leukemia activity and neutralized cardiotoxicityEntrapment of viral capsids in nuclear PML cages is an intrinsic antiviral host defense against varicella-zoster virus.Characterisation of genome-wide PLZF/RARA target genes.Control of antioxidative response by the tumor suppressor protein PML through regulating Nrf2 activity.As4S4 targets RING-type E3 ligase c-CBL to induce degradation of BCR-ABL in chronic myelogenous leukemia.Mutant p53 protein is targeted by arsenic for degradation and plays a role in arsenic-mediated growth suppression.Targeting catalase but not peroxiredoxins enhances arsenic trioxide-induced apoptosis in K562 cells.Mitogen-activated protein kinase extracellular signal-regulated kinase 2 phosphorylates and promotes Pin1 protein-dependent promyelocytic leukemia protein turnover.Treatment of acute promyelocytic leukemia with single-agent arsenic trioxide.Mutations of Epigenetic Modifier Genes as a Poor Prognostic Factor in Acute Promyelocytic Leukemia Under Treatment With All-Trans Retinoic Acid and Arsenic TrioxideSUMO deconjugation is required for arsenic-triggered ubiquitylation of PMLPML nuclear bodies: assembly and oxidative stress-sensitive sumoylation.A metabolic prosurvival role for PML in breast cancer.The role of PML ubiquitination in human malignancies.Targeting Transcription Factors in CancerMethylated arsenic metabolites bind to PML protein but do not induce cellular differentiation and PML-RARα protein degradationAuranofin induces apoptosis by ROS-mediated ER stress and mitochondrial dysfunction and displayed synergistic lethality with piperlongumine in gastric cancerArsenic suppresses cell survival via Pirh2-mediated proteasomal degradation of ΔNp63 protein.The interferon-induced antiviral protein PML (TRIM19) promotes the restriction and transcriptional silencing of lentiviruses in a context-specific, isoform-specific fashion.Arsenic trioxide stabilizes accumulations of adeno-associated virus virions at the perinuclear region, increasing transduction in vitro and in vivo.New Strategies to Direct Therapeutic Targeting of PML to Treat CancersSUMO5, a Novel Poly-SUMO Isoform, Regulates PML Nuclear Bodies.PML, SUMOylation, and SenescenceInduction of autophagy is a key component of all-trans-retinoic acid-induced differentiation in leukemia cells and a potential target for pharmacologic modulationComprehensive mutational analysis of primary and relapse acute promyelocytic leukemia.Transcription and methylation analyses of preleukemic promyelocytes indicate a dual role for PML/RARA in leukemia initiation.
P2860
Q24302645-96502514-CE81-4F53-8418-F6EB858C422FQ24307375-C68D524A-1F97-4C7A-9CF1-3A6FFFDF806FQ24307923-BD5D0862-D1D8-442A-B674-F93F3501308DQ24338903-C9DD930C-E4A7-4D85-9816-54944C1A5138Q24605527-99FB8411-89C1-4299-994D-6C78E777DD71Q26825809-8C274009-4D13-4C93-AF4E-C432F623C71BQ26853348-CC48857C-6663-4458-AAED-CBBCB7734758Q26866544-9FFE36C8-3D87-40B3-92AD-D1050A816F2DQ26991440-DBBCB9B3-C887-4CF2-8867-A3864C91C892Q27023202-7B06AF90-3DB0-44A7-B105-3AD4CBF8A06CQ27852289-F4E12A25-AF02-4473-BE63-59BC2FBEC650Q28083807-B0A8E208-A16D-4602-8643-EA687C28E29DQ28087213-A206710A-1379-4701-ABEF-4BD841E0DFC0Q28389752-2A07CF57-CF7A-454A-9A72-578572EB27A5Q28542497-B1EB6095-8CE2-4031-B0D5-D8E92073FEEDQ33815559-3B513DF5-E001-4B9D-9C86-B6F0BF27BF79Q34031285-95DCDF33-7681-42EF-B7AA-BAC248589C34Q34081454-C087265C-D3E0-405F-B4D4-7A591B23CA79Q34411016-C119B7B6-0467-4B8C-BDAA-A8F9ECA7319CQ34978872-1C503F50-4502-4E76-BB50-BEB4CB0DC5AFQ35223411-981AE153-FDE5-4084-9A27-1443C009FC1DQ35639937-B8774DE0-97E1-4829-8D5A-10B0B57E707CQ35640744-728FE916-EEE0-4879-ABBA-CB843EA814BAQ35949253-381D7797-44C0-45D4-A18B-FFB9A3A64EE3Q36155500-124D8BEB-4C8E-4108-B672-E7678B30E7EFQ36191698-31F61AC5-8282-43A0-A1A2-3CE1BD58A1F0Q36208566-9E8E8C7E-16E2-48F4-B21E-EC8F1F8BDD6DQ36223994-4E03A283-9C75-4F15-8119-3DB0B7261B2AQ36347511-C4ADF184-BAE1-4553-B435-9FA3737D32D2Q36413252-C5C1AFB5-E86E-40BA-8404-A8A0E1F53354Q36546701-4BD7EEF1-512D-482B-985E-1BCEDB4BB553Q36579412-4A411C9F-9630-462E-BBE0-882FA6B93716Q36714770-B1F13C4C-8DA9-41F1-BFB9-BDDAB26FBD50Q36760126-CBDD95CD-614D-49B9-957A-FF3AE625FBB9Q36850742-6D597D00-E5B5-4A1A-AB85-38B91BDD4532Q36925532-363D2922-540B-4E63-B7E4-FED65A65C577Q36981640-9CE4344C-2FD4-46CD-9881-BEBA1B077461Q37103762-06ADA90D-DAF2-4C8F-86CA-33165FA34224Q37150061-2BC75BE2-8330-46D1-840B-9E4DFA2E4E35Q37216371-94ABA475-04FB-406C-8799-1ABD0638A302
P2860
PML/RARA oxidation and arsenic binding initiate the antileukemia response of As2O3.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
PML/RARA oxidation and arsenic binding initiate the antileukemia response of As2O3.
@en
PML/RARA oxidation and arsenic binding initiate the antileukemia response of As2O3.
@nl
type
label
PML/RARA oxidation and arsenic binding initiate the antileukemia response of As2O3.
@en
PML/RARA oxidation and arsenic binding initiate the antileukemia response of As2O3.
@nl
prefLabel
PML/RARA oxidation and arsenic binding initiate the antileukemia response of As2O3.
@en
PML/RARA oxidation and arsenic binding initiate the antileukemia response of As2O3.
@nl
P2093
P50
P1433
P1476
PML/RARA oxidation and arsenic binding initiate the antileukemia response of As2O3.
@en
P2093
Brian Raught
Caroline Berthier
Hassane Soilihi
Laurent Peres
Marion Jeanne
Omar Ferhi
Stéphanie Duffort
Valérie Lallemand-Breitenbach
P356
10.1016/J.CCR.2010.06.003
P577
2010-07-01T00:00:00Z